Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition

Chemotherapy-induced side effects restrain anti-tumor efficiency, with hyperlipidemia being the most common accompanying disease to cause treatment failure. In this work, a chimeric peptide-engineered nanomedicine (designated as PRS) was fabricated for the synergistic suppression of tumor growth and...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Hua, Zheng, Rongrong, Wu, Ningxia, Hu, Jiaman, Wang, Ruixin, Chi, Jianing, Zhang, Wei, Zhao, Linping, Cheng, Hong, Chen, Ali, Li, Shiying, Xu, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610039/
https://www.ncbi.nlm.nih.gov/pubmed/37896137
http://dx.doi.org/10.3390/pharmaceutics15102377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610039/
https://www.ncbi.nlm.nih.gov/pubmed/37896137
http://dx.doi.org/10.3390/pharmaceutics15102377

Ejemplares similares